Editorial · 31 Dec 2025
Conference abstractPublished 2022
Dysfunction of the salivary and lacrimal glands after radioiodine treatment: Preliminary results of a self-controlled study in France
Institut de Radioprotection et de Sûreté Nucléaire, France Sorbonne University, France INSERM, France AMAREXIA, France University Hospitals Pitié Salpêtrière- Charles Foix, France
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
radioiodine (131I) therapy of differentiated thyroid cancer, salivary and lacrimal glands may become inflamed, leading to dysfunctions. The incidence of these dysfunctions after 131I-therapy is poorly known, and no clinical or genetic factors have been identified to date to define patients at risk. The aims of this study are 1) to characterize the dysfunction of salivary and lacrimal glands after 131I-therapy, 2) to identify risk factors of salivary and lacrimal dysfunction. START (Salivary dysfuncTion After Radioiodine Treatment) is a prospective study including 139 patients, candidates for a 131I-therapy in the context of their differentiated thyroid cancer (45 and 94 patients in 1.1GBq and 3.7GBq groups respectively). The follow-up was based on 2 scheduled visits: immediately before 131I-therapy (T0) and 6-months after (T6). At each visit, questionnaires on salivary disorders (validated French tool) and dry eye (OSDI© Questionnaire) were administered, and individual salivary flow measurements (without and with salivary gland stimulation) were performed. Descriptive analyses and paired comparisons tests between T0 and T6 were computed. The T6 follow-up started in March 2021, and is still ongoing. Complete information was provided for 122 patients (71% women, mean age=47.4 (±14.3) y). At 6 months after 131I-therapy, stimulated saliva flow rate decreased (from 6.98 (±3.35) to 6.07 (±3.15) mL/min, p<0.01), as well as the difference between stimulated and unstimulated saliva flow rates (from 1.40 (±0.67) to 1.21 (±0.63) mL/min, p<0.01). Also, after 131I-therapy, 19% and 21% of the study population reported dry eye or dry mouth feeling, respectively. This work presents preliminary results of the START study, showing a decrease in salivary and lacrimal gland activity after 131I-therapy. Further analyses will be performed, including saliva biochemical composition, genetic and epigenetic variants, and dose-response relationships (using dosimetric reconstructions).
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Endocrinology & Diabetes Research.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Diabetes Research
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Clemence Baudin”
- BylineArticles whose byline prints “Marie-Odile Bernier”
- BylineArticles whose byline prints “Charlotte Lussey-Lepoutre”
- BylineArticles whose byline prints “Alice Bressand”
- BylineArticles whose byline prints “Camille Buffet”
- BylineArticles whose byline prints “Laurence Leenhardt”
- BylineArticles whose byline prints “Fabrice Menegaux”
- BylineArticles whose byline prints “Marine Soret”
